InsiderTrades

Form 4 for MNPR Monopar Therapeutics

Accepted 2023-04-04 00:00:00 ET · period of report 2023-03-31 · accession 0001437749-23-009330 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-04-04 2023-03-31 MNPR Cittadine Andrew COO M - OptEx — +4,063 31.0K +15% —
D 2023-04-04 2023-03-31 MNPR Cittadine Andrew COO F - Tax $1.39 -1,154 29.8K -4% -$1,604
D 2023-04-04 2023-03-31 MNPR Cittadine Andrew COO M - OptEx $0.00 -4,063 44.7K -8% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-03-31 M A 4,063 — 30,957 D — — (F1) Represents shares acquired on vesting and settlement of restricted stock units.
2 Common Common Stock 2023-03-31 F D 1,154 $1.39 29,803 D — — (F3) Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
3 Derivative Restricted Stock Units 2023-03-31 M D 4,063 $0.00 44,687 D — · — to — 4,063 Common Stock (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F2) On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.